JERUSALEM Teva Pharmaceutical Industries has announced its settlement of its patent infringement lawsuit over its generic version of a popular contraceptive.
Teva said it has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the suit in the U.S. District Court for the District of New Jersey related to Teva’s generic Ortho Tri-Cyclen Lo. Under the terms of the settlement, Teva will obtain a release for past sales of its generic product, in exchange for an undisclosed royalty payment. Teva also will obtain a license to re-enter the market on December 31, 2015, or earlier in certain circumstances.
The settlement will not become effective until the court enters a proposed consent judgment upholding the validity and enforceability of Ortho’s patent.